Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc. continues to demonstrate a strong potential for growth as it advances its clinical programs, particularly with rhenium (186Re) obisbemeda, aimed at treating high-unmet-need conditions such as recurrent glioblastoma and leptomeningeal metastases. The positive feedback from the FDA regarding the possibility of an accelerated approval pathway reinforces the therapy's promising profile and illustrates the company's commitment to addressing the substantial demand for new treatments in the oncology space. Additionally, the recent capital raise of approximately $15 million enhances the company's financial stability and operational flexibility, positioning Plus Therapeutics favorably as it prepares for pivotal trials and scales up manufacturing capabilities.

Bears say

The financial outlook for Plus Therapeutics Inc appears negative primarily due to a significant reduction in the 12-month price target from $2.00 to $1.00 per diluted share, reflecting anticipated challenges in market performance. The company's reliance on equity offerings and associated warrants further complicates its financial stability, raising concerns about dilution for existing shareholders. Additionally, the uncertainty surrounding the efficacy of rhenium (186Re) obisbemeda, particularly in comparison to existing treatments and the variability in median overall survival reported in previous studies, contributes to an unfavorable risk assessment for the company's prospects in the oncology market.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.